Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Chitogel is a biodegradable, hydrogel-based nasal dressing designed for use after endoscopic sinus surgery. It is composed of chitosan, dextran, and glycerol—natural ingredients that together provide hemostatic (bleeding control), anti-adhesion, antibacterial, and wound-healing properties. The gel acts as a space-occupying packing to separate tissues compromised by surgical trauma, prevent adhesions between mucosal surfaces in the nasal cavity, minimize ostial stenosis (narrowing of sinus openings), and control minimal bleeding through tamponade effect and platelet aggregation. Clinical studies have shown that Chitogel significantly reduces post-surgical complications such as adhesions, edema, granulation tissue formation, crusting, infection rates, and revision surgeries while promoting healthy wound healing and supporting restoration of the sinus microbiome[1][2][3][4][5][7][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Chitogel.